Kristi Rosa

Associate Editorial Director, OncLive®
Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. She helped launch the rapidly growing infectious disease news resource Contagion, strengthened the Rare Disease Report, of HCPLive, and now oversees OncLive and its flagship publication OncologyLive. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

Articles

Adagrasib Shows Early Activity in KRAS G12C+ NSCLC, CRC, and Other Solid Tumors

October 26th 2020

Adagrasib, a potent and selective inhibitor of KRAS G12C, showcased encouraging clinical activity with an acceptable safety profile in patients with KRAS G12C–positive non–small cell lung cancer, colorectal cancer, and other solid tumors.

Patritumab Deruxtecan Poised for Phase 2 Exploration in HER3+ Advanced CRC

October 26th 2020

The novel HER3-targeted antibody-drug conjugate patritumab deruxtecan is currently being investigated in a phase 2 trial as a potential treatment for patients with advanced or metastatic colorectal cancer who are resistant, refractory, or intolerant to at least 2 previous lines of systemic therapy.

Afatinib Efficacious in EGFR+ NSCLC Harboring Major Uncommon Mutations, Irrespective of Ethnicity

October 23rd 2020

Afatinib was found to be effective when used in Asian and non-Asian patients with non–small cell lung cancer with major uncommon and compound EGFR mutations, irrespective of ethnicity.

Real World Data Show Afatinib as Effective, Safe in Second-Line Metastatic Squamous Lung Cancer

October 21st 2020

Afatinib was found to be effective and well tolerated when used as a second-line treatment in patients with metastatic squamous carcinoma of the lung.

Onvansertib Combo Achieves Disease Control, Overcomes Abiraterone Resistance in mCRPC

October 20th 2020

The combination of onvansertib plus abiraterone acetate and prednisone achieved disease control in patients with metastatic castration-resistant prostate cancer who had initial resistance to abiraterone.

FDA Grants Priority Review to Adjuvant Osimertinib for Early-Stage EGFR+ Lung Cancer

October 20th 2020

The FDA has granted osimertinib a priority review designation to a supplemental new drug application for the adjuvant treatment of patients with early-stage EGFR-mutated non–small cell lung cancer following complete tumor resection with curative intent.

Pembrolizumab Combos Showcase Promising Safety, Antitumor Activity in NSCLC

October 19th 2020

Pembrolizumab has demonstrated promising activity when used in combination with chemotherapy or quavonlimab in select patients with nonsquamous or advanced non–small cell lung cancer.

FDA Grants Priority Review to Nivolumab Plus Cabozantinib in Advanced RCC

October 19th 2020

The FDA has granted a priority review designation to a supplemental biologics license application and supplemental new drug application for nivolumab plus cabozantinib for the treatment of patients with advanced renal cell carcinoma.

KTE-X19 Granted Positive EU Opinion for Relapsed/Refractory MCL

October 16th 2020

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for KTE-X19 as a treatment in adult patients with relapsed/refractory mantle cell lymphoma who previously received 2 or more lines of systemic therapy, including a BTK inhibitor.

NICE Recommends Isatuximab Plus Pomalidomide/Dexamethasone for Relapsed/Refractory Myeloma

October 16th 2020

The United Kingdom’s National Institute for Health and Care Excellence has recommended isatuximab-irfc in combination with pomalidomide and dexamethasone as a treatment option for select patients with relapsed/refractory multiple myeloma.

Nivolumab Nears EU Approval for Second-Line Esophageal Squamous Cell Carcinoma

October 16th 2020

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for nivolumab in the treatment of adult patients with unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma following previous fluoropyrimidine- and platinum-based chemotherapy.

FDA Grants Full Approval to Venetoclax Combo in Newly Diagnosed AML

October 16th 2020

The FDA has granted regular approval to venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine for patients with newly diagnosed acute myeloid leukemia who are 75 years or older or who have comorbidities precluding intensive induction chemotherapy.

Guadecitabine Fails to Significantly Improve OS in Previously Treated AML and MDS/CMML

October 15th 2020

Guadecitabine failed to result in a statistically significant improvement in overall survival compared with physician’s choice of alternative therapy in previously treated adult patients with acute myeloid leukemia and myelodysplastic syndromes or chronic myelomonocytic leukemia.

FDA Approves Pembrolizumab for Relapsed/Refractory Classical Hodgkin Lymphoma

October 15th 2020

The FDA has approved an expanded label for pembrolizumab for use as a monotherapy in the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma and pediatric patients with refractory classical Hodgkin lymphoma, or classical Hodgkin lymphoma that has relapsed after 2 or more lines of therapy.

Sipuleucel-T Plus Androgen-Receptor Signaling Pathway Inhibitors Boosts OS in Real-World mCRPC Analysis

October 15th 2020

The addition of sipuleucel-T to the androgen-receptor signaling pathway inhibitors abiraterone acetate or enzalutamide reduced the risk of death by 41% and extended median overall survival by 14.5 months in patients with metastatic castration-resistant prostate cancer, irrespective of treatment order.

Copanlisib/Rituximab Prolongs PFS in Relapsed Indolent Non-Hodgkin Lymphoma

October 15th 2020

Copanlisib in combination with rituximab prolonged progression-free survival in patients with non-Hodgkin lymphoma who relapsed following 1 or more previous lines of rituximab-based therapy.

FDA Approval Sought for Pacritinib in Myelofibrosis With Severe Thrombocytopenia

October 13th 2020

A rolling submission of a new drug application for the JAK2/FLT3 inhibitor pacritinib has been initiated for patients with myelofibrosis and severe thrombocytopenia defined as platelet counts of less than 50,000 μL.

Mogamulizumab Significantly Boosts Outcomes in CTCL With Blood Involvement

October 13th 2020

Higher levels of blood tumor involvement were linked with more favorable outcomes in patients who received treatment with mogamulizumab compared with vorinostat in patients with 2 types of cutaneous T-cell lymphoma.

Enfortumab Vedotin Demonstrates Durable Responses in Advanced Urothelial Cancer

October 12th 2020

Enfortumab vedotin elicited durable responses in patients with locally advanced or metastatic urothelial cancer who received previous treatment with a PD-1/PD-L1 inhibitor, have not been given a platinum-containing chemotherapy, and are not eligible for cisplatin.

Avatrombopag Falls Short in Chemotherapy-Induced Thrombocytopenia

October 9th 2020

Avatrombopag failed to meet the composite primary end point of avoiding platelet transfusions, chemotherapy dose reductions by 15% or greater, and chemotherapy dose delays by 4 days or more in patients with solid tumors and chemotherapy-induced thrombocytopenia.

x